Incidence of Hemorrhagic Complications among Patients Treated with Thrombolytic in Erbil City, Iraq


Background: Recombinant tissue-type plasminogen activator is an option of treatment forsuspected occlusive vascular thrombi and its sequel (transmural myocardial infarction, pulmonaryembolism, and ischemic stroke). The most important concern associated with those patients is thefear of hemorrhagic complications.Objectives: To evaluate the incidence and risk factors of bleeding following the use of recombinanttissue-type plasminogen activator.Materials and methods: This prospective study was conducted in the Intensive Care Units ofRoj-halat Emergency Hospital and Rizgary Teaching Hospital in Erbil city, Iraq. The durationof the study was through the period from 1st of June, 2016 to 1st of March, 2017. A convenientsample of 100 patients was selected. The patients were followed after their admission to IntensiveCare Units for 24 hours after their treatment with recombinant tissue-type plasminogen activatorto explore their complications.Results: Bleeding complication represented 10% of patients treated with recombinant tissue-typeplasminogen activator (50% for each major and minor bleeding). There was a significant associationbetween increased age of patients treated with recombinant tissue-type plasminogen activatorand bleeding (P-value = 0.01). Patients with a history of hypertension, diabetes, and smokingwere significantly associated with a bleeding complication of recombinant tissue-type plasminogenactivator (P-value <0.05).Conclusion: The incidence of bleeding among patients after treatment with recombinant tissuetype plasminogen activator in the intensive care unit was acceptable. The age, diabetes, smoking,and hypertension were risk factors for increasing the bleeding complications in subjects treatedwith recombinant tissue-type plasminogen.